Loading...
Zydus Lifesciences Limited — Glibenclamide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Glibenclamide · $116.0K export value · DGFT Verified
Zydus Lifesciences Limited is the #7 Indian exporter of Glibenclamide with $116.0K in export value and 22 verified shipments. Zydus Lifesciences Limited holds a 0.3% market share in Glibenclamide exports across 5 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| KENYA | $48.1K | 11 | 41.5% |
| TANZANIA | $34.8K | 4 | 30.0% |
| UGANDA | $20.8K | 3 | 17.9% |
| YEMEN, DEMOCRATIC | $11.2K | 3 | 9.7% |
| UNITED ARAB EMIRATES | $1.0K | 1 | 0.9% |
Zydus Lifesciences Limited exports Glibenclamide to 5 countries. The largest destination is KENYA accounting for 41.5% of Zydus Lifesciences Limited's Glibenclamide shipments, followed by TANZANIA (30.0%) and UGANDA (17.9%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ABACUS PHARMA (A) LTD | TANZANIA | $34.8K | 4 |
| ABACUS PHARMA (AFRICA) LTD | UGANDA | $34.5K | 9 |
| ABACUS PHARMA AFRICA LTD | UGANDA | $16.6K | 2 |
| ABACUS PHARMA (AFRICA) LIMITED | KENYA | $11.8K | 2 |
| AL-JABAL DRUGS AND MEDICAL APPLIANC | YEMEN, DEMOCRATIC | $11.2K | 3 |
| ABACUS PHARMA (AFRICA) LTD., | UGANDA | $6.0K | 1 |
India exported $2.1M worth of Glibenclamide through 930 shipments from 194 suppliers to 100 countries, serving 335 buyers globally. Zydus Lifesciences Limited contributes $116.0K to this total, accounting for 0.3% of India's Glibenclamide exports. Zydus Lifesciences Limited ships Glibenclamide to 5 countries through 7 buyers.
Zydus Lifesciences Limited's average Glibenclamide shipment value is $5.3K per consignment, based on 22 shipments totaling $116.0K. The largest destination is KENYA (41.5% of Zydus Lifesciences Limited's Glibenclamide exports).
Zydus Lifesciences Limited ranks #7 among 194 Indian Glibenclamide exporters with a 0.3% market share. The top 3 exporters are MEDOPHARM ($420.3K), M. J. BIOPHARM PRIVATE LIMITED ($375.5K), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($274.9K). Zydus Lifesciences Limited processed 22 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BETANASE 5MG TABLETS (GLIBENCLAMIDE) 5X3 | $20.8K | 4 |
| BETANASE 5 MG TABS(GLIBENCLAMIDE)(5X3X10 | $19.1K | 2 |
| BETANASE 5MG TABLETS (GLIBENCLAMIDE TABSBP) 5X3X10NOS | $11.8K | 2 |
| PHARMACEUTICALS MEDICINE FOR HUMAN USE-BETANASE 5 MG TABS (GLIBENCLAMIDE 5MG)5X3X10-QTY.12,450.000 PAC AS PER INVOICENOS | $11.2K | 3 |
| BETANASE 5MG TABLETS GLIBENCLAMIDE 5X3 | $9.1K | 1 |
| BETANASE 5 MG TABS (GLIBENCLAMIDE) 5X3X10 | $8.8K | 1 |
| BETANASE5 MG GLIBENCLAMIDE TABLET BP 5X3X10 | $7.6K | 1 |
| BETANASE 5 MG TABS (GLIBENCLAMIDE) 5X3X1 | $6.9K | 1 |
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | CAPLIN POINT LABORATORIES LIMITED | $169.2K | 17 | 5 | $10.0K |
| 6 | LINCOLN PHARMACEUTICALS LTD | $124.9K | 16 | 5 | $7.8K |
| 7 | ZYDUS LIFESCIENCES LIMITED ★ | $116.0K | 22 | 5 | $5.3K |
| 8 | MEDICAMEN BIOTECH LIMITED | $110.9K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 133 | 14.3% |
| NHAVA SHEVA SEA (INNSA1) | 130 | 14.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 99 | 10.6% |
| JNPT/ NHAVA SHEVA SEA | 61 | 6.6% |
| JNPT | 45 | 4.8% |
| Bombay Air | 33 | 3.5% |
| MUNDRA SEA | 32 | 3.4% |
| AHEMDABAD ICD | 27 | 2.9% |
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Glibenclamide, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Glibenclamide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Glibenclamide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
| WORLD HEALTH ORGANIZATION | UNITED ARAB EMIRATES | $1.0K | 1 |
Zydus Lifesciences Limited supplies Glibenclamide to 7 buyers globally. The largest buyer is ABACUS PHARMA (A) LTD (TANZANIA), followed by ABACUS PHARMA (AFRICA) LTD (UGANDA) and ABACUS PHARMA AFRICA LTD (UGANDA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| BETANASE 5MG TABLETS(GLIBENCLAMIDE)(5X3X |
| $6.0K |
| 1 |
| BETANASE 5MG TABLETS (GLIBENCLAMIDE) 5X3X10 | $5.3K | 2 |
Zydus Lifesciences Limited exports 13 distinct Glibenclamide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BETANASE 5MG TABLETS (GLIBENCLAMIDE) 5X3 with 4 shipments worth $20.8K.
| 11 |
| 8 |
| $10.1K |
| 9 | RUSAN PHARMA LIMITED | $107.8K | 3 | 1 | $35.9K |
Zydus Lifesciences Limited ranks #7 among 194 Indian Glibenclamide exporters. Average shipment value of $5.3K compared to the market average of $11.0K. The closest competitors by value are CAPLIN POINT LABORATORIES LIMITED and LINCOLN PHARMACEUTICALS LTD.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 100+ countries, 335+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Glibenclamide. For current shipment-level data, contact TransData Nexus.